Sponsors (10)
The bill modernizes and speeds sunscreen ingredient approval, increases transparency, and reduces animal testing—improving access and prevention—while trading off increased regulatory variability, potential safety uncertainty, added costs for industry and FDA, and risks to proprietary information.
Millions of consumers (children, young adults, parents, seniors, and uninsured people) could gain faster access to new or reformulated over‑the‑counter sunscreen ingredients because the FDA will accept historical, real‑world, and alternative nonclinical evidence alongside traditional data, speeding approvals.
Broader public awareness and a required regulatory emphasis on sunscreen as a prevention tool could lower future skin cancer and melanoma incidence by encouraging sun‑safe behaviors and stronger prevention campaigns.
The bill reduces reliance on animal testing by requiring FDA to consider specified nonclinical non‑animal tests and by tracking progress on alternatives, encouraging faster adoption of in vitro and computational methods.
Allowing observational, real‑world, and alternative nonclinical evidence in place of or to supplement traditional clinical trials could raise uncertainty about long‑term safety and increase the risk of unforeseen adverse effects for children, parents, seniors, and other consumers.
Broad acceptance of alternative test methods and variable evidence standards could produce inconsistent regulatory decisions across products, leading to uneven consumer protections unless strong implementation safeguards are enforced.
New testing and evidence requirements may impose costs on manufacturers (especially small businesses) that could be passed to consumers through higher prices or reduce market competition.
Based on analysis of 5 sections of legislative text.
Directs FDA to adopt standards allowing real‑world evidence and certain non‑animal tests for evaluating OTC sunscreen active ingredients and to apply those standards to pending submissions.
Directs the FDA to create clear standards for evaluating the safety and effectiveness of over‑the‑counter sunscreen active ingredients, including allowing real‑world evidence and validated nonclinical non‑animal tests. It also requires the FDA to apply those standards when issuing a final administrative order on pending sunscreen ingredient submissions, to issue guidance on non‑animal alternatives within 180 days, and to provide annual reports on implementation and application of the new standards to two congressional committees and on the FDA website.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to improve the regulatory review process to determine the safety and effectiveness of nonprescription sunscreen active ingredients, and for other purposes.
Introduced June 3, 2025 by John Joyce · Last progress June 3, 2025